文献速递心外重症与机械循环支持肺外科

体外生命支持作为肺动脉高压桥接:高容量单中心经验

Extracorporeal life support bridge for pulmonary hypertension: A high-volume single-center experience.
PubMed 文献 · J Heart Lung Transplant · 2019-09-12

该单中心回顾性分析纳入98例世界肺动脉高压研讨会分组1、3、4或5组肺动脉高压成人患者,接受体外生命支持作为移植桥接或非移植桥接。结果显示30天生存率73.5%,出院生存率54.1%,移植后桥接患者出院生存率100%。结论认为专业多学科团队实施的体外生命支持可用于晚期肺动脉高压管理。

要点

  • 体外生命支持可作为肺动脉高压患者移植桥接或非移植桥接(恢复、非移植手术、移植后)。
  • 全体队列30天生存率73.5%,出院生存率54.1%。
  • 移植后桥接患者出院生存率100%,非移植手术桥接64.7%。

核心结论

  • 专业多学科团队实施的体外生命支持可用于晚期肺动脉高压的移植桥接或非移植桥接管理。

研究设计与样本

  • 回顾性分析2010年1月1日至2018年8月18日哥伦比亚大学医学中心/纽约长老会医院98例世界肺动脉高压研讨会分组1、3、4或5组肺动脉高压成人患者。

主要发现

  • 98例患者中54例(55%)接受体外生命支持作为移植桥接,44例(45%)为非移植桥接,包括19例恢复桥接、17例非移植手术桥接和8例移植后桥接。
  • 全体队列中67例(68.4%)接受静脉-动脉体外生命支持,31例(31.6%)接受静脉-静脉体外生命支持。
  • 83例中52例(63%)脱离有创机械通气,85.2%的移植桥接肺动脉高压患者在体外生命支持期间行走。
  • 全体30天生存率73.5%,至体外生命支持撤机生存率66.3%,至出院生存率54.1%。
  • 8例移植后桥接患者全部(100%)存活至出院,非移植手术桥接患者出院生存率64.7%,移植桥接患者至肺移植生存率59.3%(32例)。

关键数值与推荐

  • 早期移植桥接使用静脉-静脉体外生命支持者出院生存差于初始静脉-动脉体外生命支持者,影响总体生存,导致当前时代在移植后桥接、非移植手术桥接和选择恢复桥接病例中限制静脉-静脉体外生命支持使用。

临床怎么用

  • 谨慎选择体外生命支持插管配置,个体化优化肺动脉高压药物治疗,避免气管插管可能是管理这些复杂患者的有效策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Application of extracorporeal life support (ECLS) for advanced pulmonary hypertension (PH) is evolving and may be deployed as a bridge to transplantation (BTT) or in one of several non-BTT uses, such as bridge to recovery (BTR) to the chronic PH clinical state in the setting of an acute PH trigger, bridge through non-transplant surgery (BTNTS), or bridge post-transplantation (BPT). METHODS: We conducted a retrospective analysis of all adult patients with World Symposium on Pulmonary Hypertension Group 1, 3, 4, or 5 PH who received ECLS at Columbia University Medical Center/New York Presbyterian Hospital between January 1, 2010 and August 18, 2018. We describe patient characteristics, outcomes, and our approach to medical and surgical management of these patients. RESULTS: There were 98 patients with significant PH in the cohort (54 female; median age, 48 years [interquartile range, 32-58]). Of these, 44 (45%) patients with PH received ECLS as non-BTT with intent to recover back to their baseline functional state, optimize therapy, or support through a definitive surgery, including 19 BTR, 17 BTNTS, and 8 BPT, and 54 (55%) patients received ECLS as BTT. In the overall cohort, 67 (68.4%) patients received venoarterial ECLS and 31 (31.6%) received venovenous (VV) ECLS. Out of 83 patients, 52 (63%) were liberated from invasive mechanical ventilation, and 85.2% of BTT patients with PH ambulated while on ECLS. Management of PH medications was individualized, often requiring titration with use of inhaled pulmonary vasodilators increased after cannulation in non-BTT. Overall 30-day survival was 73.5%, survival to ECLS decannulation was 66.3%, and survival to hospital discharge was 54.1%. All 8 BPT patients (100%) survived to hospital discharge, 64.7% of BTNTS patients survived to hospital discharge, and 32 (59.3%) BTT patients survived to lung transplantation. Early-era use of VV-ECLS for BTT had worse survival to discharge than those initially configured with venoarterial ECLS, impacting the overall survival and leading to limited use of VV-ECLS in the current era for BPT, BTNTS, and select BTR cases. CONCLUSIONS: ECLS instituted by a specialized, multidisciplinary team has a role in the management of advanced PH as BTT or as non-BTT (including BTR, BTNTS, and BPT). Careful selection of ECLS cannulation configurations, patient-specific optimization of PH medical therapies, and avoidance of endotracheal intubation may be effective strategies in managing these complex patients.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Rosenzweig EB, Gannon WD, Madahar P, et al. Extracorporeal life support bridge for pulmonary hypertension: A high-volume single-center experience. J Heart Lung Transplant. 2019. PMID: 31582284. doi:10.1016/j.healun.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。